Analyst consensus rating
Cartesian Therapeutics Analyst Rating: none
Direct answer
Cartesian Therapeutics's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $33.67.
Forecast evidence checked October 19, 2026.
Get free Cartesian Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.27
- Average price target
- $33.67
- High price target
- $44.00
- Low price target
- $16.00
- Low target gap
- +155.2%
- Target upside
- +436.9%
- High target gap
- +601.8%
- Target range width
- 446.6%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Cartesian Therapeutics?
Cartesian Therapeutics has a verified none consensus. The same dataset has an average price target of $33.67.
How far are Cartesian Therapeutics's low and high targets from the recorded price?
The low target implies +155.2%, while the high target implies +601.8%.
How many analysts are included in Cartesian Therapeutics's consensus?
The verified consensus includes 6 analysts.
How is Cartesian Therapeutics's target upside or downside calculated?
The average target of $33.67 is divided by the recorded price of $6.27, then one is subtracted to produce +436.9%. This does not guarantee a future return.
When was Cartesian Therapeutics's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.